Back

Aspirin, not without bleeding risk in the real world: results of a UK cohort study evaluating the use of antiplatelet therapy for stroke prevention in atrial fibrillation (AF)

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation III Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Essra Ridha

Bristol-Myers Squibb Pharmaceuticals Limited , London (United Kingdom of Great Britain & Northern Ireland)

24 More presentations in this session

Presentation thumbnail
Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial
Professor D. Xavier (Bangalore, IN)
Abstract Slides
Presentation thumbnail
Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers
Doctor C. Gatti (Ravenna, IT)
Abstract Slides
Presentation thumbnail
High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation
Doctor D. Iglesias (Santiago de Compostela, ES)
Abstract Slides
Presentation thumbnail
CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation
Doctor J. Wieczorek (Katowice, PL)
Abstract Slides
Presentation thumbnail
Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation
Doctor A. Parwani (Berlin, DE)

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation III

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources